Volume 15, Issue 5 (September & October- In Press 2024)
BCN 2024, 15(5): 0-0 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ghasempour S, Maghsoudi N, Manaheji H, Ghasemi R, Jaafari Suha A, Zaringhalam J. A New Dipeptide H-MGL Partially Ameliorates Memory Impairment in an STZ-Induced Alzheimer Model in Male Rats. BCN 2024; 15 (5)
URL: http://bcn.iums.ac.ir/article-1-2721-en.html
URL: http://bcn.iums.ac.ir/article-1-2721-en.html
Sarieh Ghasempour1 
, Nader Maghsoudi2 , Homa Manaheji1 , Rasoul Ghasemi1 , Ali Jaafari Suha1 , Jala Zaringhalam * 1
, Nader Maghsoudi2 , Homa Manaheji1 , Rasoul Ghasemi1 , Ali Jaafari Suha1 , Jala Zaringhalam * 1
1- Physiology Department, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
2- Neurobiology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
2- Neurobiology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abstract:
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is identified by the gradual decline in memory and cognitive function. It is classified by the deposition of Aβ plaques, the build-up of intracellular neurofibrillary tangle and neuron loss. Neurotrophic factors play critical role in the treatment of Alzheimer's disease. However, the utilization of such neurotrophins has encountered certain difficulties and side effects. Novel technological advancements prioritize innovative dipeptides usage, which offer fewer side effects. The present study endeavors to analyze the compound hexamethylenediamide bis-(N-monosuccinyl-glutamyl-lysine) (Lab name: H-MGL), a newly discovered neurotrophin mimetic dipeptide, with the aim of alleviating memory impairment in an intracerebroventricular single dose streptozotocin (STZ)-induced Alzheimer model in rats. We arranged 4 groups consist of sham, groups receiving STZ and STZ+H-MGL (1 and 2mg/kg). The H-MGL was administered consecutively for 14 days following STZ injection subsequently, the Morris Water Maze test was performed. The findings suggest that administration of STZ caused significantly increment in mean escape latency and mean traveled distance in acquisition days. H-MGL at a dosage of 1mg/kg failed to yield any notable improvement in rats when compared to STZ. By contrast, a dosage of 2mg/kg of H-MGL led to a significant decrease in the latency to first platform crossing and frequency of platform crossings. Consequently, the aforementioned findings have engendered the notion that H-MGL partially ameliorate cognitive impairment so it may hold promise for having low side effects to alleviate cognitive deficits in Alzheimer's disease, or potentially decreases the symptoms associated with its progression.
Type of Study: Original |
Subject:
Behavioral Neuroscience
Received: 2023/05/30 | Accepted: 2023/07/15 | Published: 2024/09/20
Received: 2023/05/30 | Accepted: 2023/07/15 | Published: 2024/09/20
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright © The Author(s);
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
